Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Research Report 2019 (Includes Business Impact of COVID-19)

                                          
"The ongoing Coronavirus (COVID-19) pandemic is re-shaping everything from global economies to product categories, pricing, and stock availability to the consumer behavior. The final report is updated to address the impact of COVID-19 on the Dipeptide Peptidase 4 (DPP-4) Inhibitors market.

Trusted Business Insights is tracking mining/oil and gas, transportation, employment services, travel arrangements, and the leisure and hospitality sector closely as they are likely to be the hardest-hit sectors. Utilities, local pharma, diagnostics, consumer goods and durables, agro chem and fertilizers, and telecommunications are the sectors that will be weathering the COVID-19 storm and most likely come out relatively unscathed. Interdependencies of sectors are factored in our research report on the Dipeptide Peptidase 4 (DPP-4) Inhibitors market."
Dipeptide Peptidase 4 (DPP-4) Inhibitors are a class of oral diabetes drugs that work by blocking the action of DPP-4, an enzyme which destroys a group of gastrointestinal hormones called incretins. Incretins help stimulate the production of insulin when it is needed (e.g. after eating) and reduce the production of glucagon by the liver when it is not needed (e.g. during digestion). They also slow down digestion and decrease appetite. So by protecting incretins from damage, DPP-4 inhibitors help regulate blood glucose levels. 
Januvia (Sitagliptin), Galvus (Vildagliptin), Onglyza (Saxagliptin), Tradjenta (Linagliptin) are the major DPP-4 drugs in the market. 

The global Dipeptide Peptidase 4 (DPP-4) Inhibitors market is valued at xx million US$ in 2018 is expected to reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Dipeptide Peptidase 4 (DPP-4) Inhibitors volume and value at global level, regional level and company level. From a global perspective, this report represents overall Dipeptide Peptidase 4 (DPP-4) Inhibitors market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan.
At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report.

The following manufacturers are covered:
    Merck
    Eli Lilly
    AstraZenica
    Boehringer Ingelheim
    Takeda Pharmaceutical Company
    BMS
    ...

Segment by Regions
    North America
    Europe
    China
    Japan

Segment by Type
    Sitagliptin
    Saxagliptin
    Linagliptin
    Alogliptin
    Vildagliptin

Segment by Application
    Hospitals
    Clinics